For local control in patients with endocrinerefractory prostate cancer, an intra-arterial chemotherapy regimen comprising methotrexate (MTX), Adriamycin (ADM), and cisplatin (CDDP) was evaluated. A total of 19 patients having a mean age of 66.4±8.8 years and a mean performance status (PS) of 1.3±1.0 were enrolled. Of these patients, 3 had proved to be resistant to initial endocrine therapy and the remaining 16 had relapsed from disease stabilization after endocrine therapy. The catheter tip was placed in the internal iliac artery in 16 cases, in the common iliac artery in 2 cases, and in the aorta in 1 case after occlusion of the contralateral feeding artery. The intra-arterial chemotherapy was performed mainly using MTX (30 mg/m2), ADM (30 mg/m2), and CDDP (50 mg/m2) as one course and was repeated for a mean of 2.9±2.3 courses. Then, in an outpatient clinic, 5-fluorouracil (5-FU), ADM, or MTX was given intra-arterially as maintenance chemotherapy until re-relapse. As based on the criteria for evaluation of nonsurgical therapy in prostate cancer proposed by the Japanese Urological Association, the prostatic lesion showed a partial response (PR) in 9 cases and no change (NC) in 10 cases. As judged from the response of prostate-specific antigen (PSA), a complete response (CR) was obtained in 6 cases, a PR, in 3 cases; and NC and progressive disease (PD), in 2 cases each. Therefore, the overall response rate was 63%. Improvement in the symptoms was observed in 83% of patients. The duration of the response was 15.1±10.5 months for the PR cases and 7.4±5.7 months for the NC cases. Furthermore, the mean survival time observed in the PR group was 38.9 months, which was better than that seen in the NC (16.4 months) and PD (10.5 months) groups. These results suggest that intra-arterial chemotherapy may become and option for the treatment of locally advanced and endocrine-refractory prostate cancers. Using a reservoir, this chemotherapy can be easily given in an outpatient clinic.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA (1993) Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J Urol 150: 411
Dawson NA, Wilding G, Weiss RB, McLeod DG, Linehan WM, Frank JA, Jacob J, Gelmann EP (1992) A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer 69: 213
Dik P, Blom JH, Schroder FH (1992) Mitomycin C and aminoglutethimide in the treatment of metastatic prostatic cancer: a phase II study. Br J Urol 70: 542
Eisenberger MA (1988) Chemotherapy of prostate cancer. NCI Monogr 7: 151
Imai K, Kawashima K, Totsuka Y, Yamanaka H (1991) Therapy for metastatic prostate cancer. Urol Surg 4: 991
Japanese Urological Association and Japanese Pathological Society (1992) General rule for clinical and pathological studies on prostatic cancer, 2nd edn. Kanahara Shuppan, Tokyo
Laurie JA, Hahn RG, Therneau TM (1992) Chemotherapy of hormonally refractory advanced prostate carcinoma: a comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 69: 1440
Rangel C, Matzkin H, Soloway MS (1992) Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology 39: 577
Whitemore WF (1973) The natural history of prostate carcinoma. Cancer 23: 1104
Yoshimoto J, Nasu Y, Akagi T, Obama T, Tsushima T, Ozaki Y, Matsumura Y, Ohmori H (1985) Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with advanced stage D adenocarcinoma of the prostate. Jpn J Urol 76: 1
About this article
Cite this article
Kuriyama, M., Takeuchi, T., Takahashi, Y. et al. Intra-arterial chemotherapy using a reservoir for endocrine-refractory prostate cancer. Cancer Chemother. Pharmacol. 35, S27–S30 (1994). https://doi.org/10.1007/BF00686915
- Prostate cancer
- Endocrine refractory tumor
- Intra-arterial chemotherapy